Scotiabank raised the firm’s price target on Vera Therapeutics (VERA) to $65 from $55 and keeps an Outperform rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Buy Rating for Vera Therapeutics: Promising Potential of Atacicept in IgA Nephropathy Treatment
- Arthur He CFA Upgrades Vera Therapeutics on Promising Phase 3 Results for Atacicept in IgAN Treatment
- H.C. Wainwright ups Vera Therapeutics target on ‘home run’ data
- Vera Therapeutics Announces Positive Phase 3 Trial Results
- Vera Therapeutics: Primary endpoint was met in ORIGIN Phase 3 trial of atacicept